Transcription factor that recognizes and binds to the AP-1 consensus motif 5'-TGA[GC]TCA-3' (PubMed:10995748, PubMed:22083952). Heterodimerizes with proteins of the FOS family to form an AP-1 transcription complex, thereby enhancing its DNA binding activity to the AP-1 consensus sequence 5'-TGA[GC]TCA-3' and enhancing its transcriptional activity (By similarity). Together with FOSB, plays a role in activation-induced cell death of T cells by binding to the AP-1 promoter site of FASLG/CD95L, and inducing its transcription in response to activation of the TCR/CD3 signaling pathway (PubMed:12618758).
Promotes activity of NR5A1 when phosphorylated by HIPK3 leading to increased steroidogenic gene expression upon cAMP signaling pathway stimulation (PubMed:17210646). Involved in activated KRAS-mediated transcriptional activation of USP28 in colorectal cancer (CRC) cells (PubMed:24623306). Binds to the USP28 promoter in colorectal cancer (CRC) cells (PubMed:24623306)
Heterodimer with either BATF3 or ATF7 (PubMed:10376527, PubMed:12087103, PubMed:15467742). Heterodimer with FOS (By similarity). Heterodimer with FOSB isoform 1 and 2 (By similarity).
Component of an AP-1 transcription factor complex composed of JUN-FOS heterodimers (By similarity). As part of the AP-1 transcription factor complex, forms heterodimers with FOSB, thereby binding to the AP-1 consensus sequence and stimulating transcription (By similarity). Interacts with FOS and FOSB isoform 1 and 2 (By similarity).
The ATF7/JUN heterodimer is essential for ATF7 transactivation activity (PubMed:10376527). Interacts with TSC22D3 (via N-terminus); the interaction inhibits the binding of active AP1 to its target DNA (By similarity). Interacts with HIVEP3 and MYBBP1A (By similarity).
Interacts with SP1, SPIB and TCF20 (PubMed:10196196, PubMed:16478997, PubMed:8663478). Interacts with COPS5; the interaction leads indirectly to its phosphorylation (PubMed:8837781). Component of the SMAD3/SMAD4/JUN/FOS/complex which forms at the AP1 promoter site (PubMed:10995748).
The SMAD3/SMAD4 heterodimer acts synergistically with the JUN/FOS heterodimer to activate transcription in response to TGF-beta (PubMed:9732876). Interacts (via its basic DNA binding and leucine zipper domains) with SMAD3 (via an N-terminal domain); the interaction is required for TGF-beta-mediated transactivation of the SMAD3/SMAD4/JUN/FOS/complex (PubMed:10995748). Interacts with methylated RNF187 (PubMed:20852630, PubMed:23624934).
Binds to HIPK3. Interacts (when phosphorylated) with FBXW7 (PubMed:14739463). Found in a complex with PRR7 and FBXW7 (PubMed:27458189).
Interacts with PRR7 and FBXW7; the interaction inhibits ubiquitination-mediated JUN degradation promoting its phosphorylation and transcriptional activity (PubMed:27458189). Interacts with RBM39 (By similarity). Interacts with PAGE4 (PubMed:24263171, PubMed:24559171, PubMed:26242913).
Interacts with ARK2N and CSNK2B; the interaction with ARK2N is mediated by CSNK2B (PubMed:31341047)
Expressed in the developing and adult prostate and prostate cancer cells
| Cancer Type | Mutation Percentage |
|---|---|
| Central Nervous System Astrocytoma Grade Iv | 0.09% |
| Lung Adenocarcinoma | 0.44% |
| Lung Small Cell Carcinoma | 0.30% |
| Lung Squamous Cell Carcinoma | 0.27% |
| Oesophagus Squamous Cell Carcinoma | 0.23% |
| Pancreas Ductal Carcinoma | 0.08% |
Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to JUN, aggregated across our SSL data sources. Click any partner node to view that gene’s page.
Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.
Total Trials Found: 20
| NCT ID | Condition | Brief Title | Phase | Status |
|---|---|---|---|---|
| NCT05066841 | Childhood Asthma | Chinese Herbal Medicine Formula Combined With Inhaled Corticosteroids for the Treatment of Mild to Persistent Asthma in Children | NA | UNKNOWN |
| NCT06972173 | Deep Breathing Maneuver, PROGRESSIVE MUSCLE RELAXATION EXERCISES | SHORT-TERM EFFECTS OF DEEP BREATHING AND PROGRESSIVE MUSCLE RELAXATION EXERCISES ON MUSCULOSKELETAL PAIN AND WELL-BEING IN HIGH SCHOOL STUDENTS | NA | COMPLETED |
| NCT01406288 | Hemolytic-uremic Syndrome, Escherichia Coli Infections | Outbreak of Hemolytic Uremic Syndrome Linked to Escherichia Coli of Serotype O104:H4 | N/A | COMPLETED |
| NCT06758622 | Neonatal Morbidity and Mortality, Intrauterine Growth Disorders (IUGR and Macrosomia), Prematurity Complications, Neonatal Infections | Analysis on the Health of Newborns in Three Hospitals, 2008-2024 | N/A | ACTIVE_NOT_RECRUITING |
| NCT02179580 | Irritable Bowel Syndrome | A Study of Xiang-Sha-Liu-Jun-Zi-Tang in Patients With Irritable Bowel Syndrome | PHASE2, PHASE3 | UNKNOWN |
| NCT02534714 | Hypovitaminosis D, Spinal Disease, Osteoporosis | Analysis of Hypovitaminosis D and Osteopenia/Osteoporosis in Spinal Disease Patients Who Underwent a Spinal Fusion at Illinois Neurological Institute, Peoria, IL., a Retrospective Review From November 1, 2012 to October 31, 2014 and Prospective Pilot From July 1, 2015-June 30, 2016 | N/A | COMPLETED |
| NCT04562428 | Hepatocellular Carcinoma | The Safety and Efficacy Evaluation of XSLJZ in Advanced Hepatocellular Carcinoma Patients With Multiple Protein Kinase Inhibitor Therapy: A Randomized, Double-Blind, Controlled Trial | PHASE4 | COMPLETED |
| NCT06670261 | Nasal Obstruction, Deviated Nasal Septum | Diagnosis of Respiratory Disorders by the Numerical Modeling. | N/A | RECRUITING |
| NCT01463852 | Chronic Lymphocytic Leukemia (CLL) | A Study of the Effect of Vinca Alkaloids on c-Jun N-terminal Kinase (JNK) Phosphorylation in Patients With Chronic Lymphocytic Leukemia (CLL) | EARLY_PHASE1 | TERMINATED |
| NCT06683937 | Immunocompromised Patients, SARS-CoV-2 Disease | Evaluation of Direct Antiviral Treatments Against SARS-CoV-2 in Immunocompromised Patients With Covid-19. A G2i Study, National Multicenter Observational and Retrospective From June 2023 to April 2024 | N/A | NOT_YET_RECRUITING |